This site is intended for UK healthcare professionals
The licence for Aclasta (zoledronate) has been extended to include the treatment of osteoporosis in men at increased risk of fracture, including those with a recent low-trauma hip fracture.
The recommended dose for the treatment of postmenopausal osteoporosis and osteoporosis in men is a single 5mg intravenous infusion administered once a year.
Further information: Novartis
The most up-to-date drug information at your fingertips.
Prescribers can now compare urea-based emollients with...
Use our constantly updated shortages tracker to check...
Join us for a short webinar series offering insights...
The MIMS table 'Antidepressants, a guide to switching...
Drugs
Conditions
News and resources
MIMS Hosted